JP2020517635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517635A5 JP2020517635A5 JP2019556860A JP2019556860A JP2020517635A5 JP 2020517635 A5 JP2020517635 A5 JP 2020517635A5 JP 2019556860 A JP2019556860 A JP 2019556860A JP 2019556860 A JP2019556860 A JP 2019556860A JP 2020517635 A5 JP2020517635 A5 JP 2020517635A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- cell
- combination
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 19
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 241000701161 unidentified adenovirus Species 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 230000027455 binding Effects 0.000 claims 8
- 201000000464 cone-rod dystrophy 2 Diseases 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 5
- 230000000174 oncolytic effect Effects 0.000 claims 5
- 244000309459 oncolytic virus Species 0.000 claims 5
- 230000009870 specific binding Effects 0.000 claims 5
- 101710199711 Early E1A protein Proteins 0.000 claims 4
- 241001135569 Human adenovirus 5 Species 0.000 claims 3
- 102000006601 Thymidine Kinase Human genes 0.000 claims 3
- 108020004440 Thymidine kinase Proteins 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108050002653 Retinoblastoma protein Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000006837 decompression Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023054969A JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488181P | 2017-04-21 | 2017-04-21 | |
| US62/488,181 | 2017-04-21 | ||
| PCT/US2018/028577 WO2018195427A2 (en) | 2017-04-21 | 2018-04-20 | Oncolytic virotherapy and immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023054969A Division JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517635A JP2020517635A (ja) | 2020-06-18 |
| JP2020517635A5 true JP2020517635A5 (OSRAM) | 2021-05-20 |
| JP7260173B2 JP7260173B2 (ja) | 2023-04-18 |
Family
ID=62196688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556860A Active JP7260173B2 (ja) | 2017-04-21 | 2018-04-20 | 腫瘍溶解性ウイルス療法および免疫療法 |
| JP2023054969A Active JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023054969A Active JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11896634B2 (OSRAM) |
| EP (1) | EP3612202A2 (OSRAM) |
| JP (2) | JP7260173B2 (OSRAM) |
| KR (2) | KR20240093758A (OSRAM) |
| CN (1) | CN110785180B (OSRAM) |
| AU (2) | AU2018254566B2 (OSRAM) |
| CA (1) | CA3060573A1 (OSRAM) |
| NZ (1) | NZ758626A (OSRAM) |
| SG (1) | SG11201909749PA (OSRAM) |
| TW (1) | TWI799411B (OSRAM) |
| WO (1) | WO2018195427A2 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6576326B2 (ja) | 2013-03-14 | 2019-09-18 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍溶解性アデノウイルス組成物 |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| KR20220163505A (ko) | 2016-02-23 | 2022-12-09 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
| AU2017222568B2 (en) | 2016-02-23 | 2020-09-10 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| AU2018254566B2 (en) * | 2017-04-21 | 2025-02-13 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| SG10201801219VA (en) * | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| WO2019202118A1 (en) * | 2018-04-20 | 2019-10-24 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| US11413315B2 (en) * | 2018-04-29 | 2022-08-16 | City Of Hope | Neural stem cell-mediated cancer treatment |
| EP4285914A3 (en) * | 2018-10-25 | 2024-02-28 | Baylor College of Medicine | Oncolytic virotherapy and immunotherapy |
| EP3917564A4 (en) * | 2019-02-01 | 2022-12-21 | NovaRock Biotherapeutics, Ltd. | ANTI-CLAUDINE 18 ANTIBODIES AND THEIR METHODS OF USE |
| CN111743923B (zh) * | 2019-03-27 | 2024-11-08 | 北京康万达医药科技有限公司 | 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用 |
| MX2021010577A (es) * | 2019-04-29 | 2021-10-13 | Mayo Found Medical Education & Res | Compuestos de union a pd-l1 multivalentes para tratar cancer. |
| WO2021091560A1 (en) * | 2019-11-07 | 2021-05-14 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| CN111632146B (zh) * | 2020-05-29 | 2021-09-28 | 中山大学 | Oat抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| CN111676245B (zh) * | 2020-06-24 | 2022-09-13 | 武汉波睿达生物科技有限公司 | 一种含有HSV-1型溶瘤病毒的NFAT-Cre-CAR-T细胞及其应用 |
| CN113913379B (zh) * | 2020-07-07 | 2024-02-06 | 深圳市菲鹏生物治疗股份有限公司 | T淋巴细胞及其应用 |
| CN113425856B (zh) * | 2021-07-07 | 2022-01-04 | 浙江康佰裕生物科技有限公司 | 一种含有基因修饰的溶瘤病毒的药物组合物及其在治疗癌症的用途 |
| WO2023076469A1 (en) * | 2021-10-29 | 2023-05-04 | Unm Rainforest Innovations | Oncolytic virotherapy compositions and methods |
| CN114032323B (zh) * | 2021-11-17 | 2023-08-08 | 云南省烟草农业科学研究院 | 一种与雪茄烟抗黑胫病基因紧密连锁的共显性ssr标记及其应用 |
| WO2024042231A1 (en) * | 2022-08-26 | 2024-02-29 | Universite De Namur | Adenovirus-based adjuvants for cancer treatment |
| WO2024229083A1 (en) * | 2023-05-03 | 2024-11-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN118930652B (zh) * | 2024-07-29 | 2025-03-11 | 北京肿瘤医院(北京大学肿瘤医院) | 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69426841T2 (de) | 1993-02-16 | 2001-09-06 | Onyx Pharma Inc | Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| US6080569A (en) | 1993-06-24 | 2000-06-27 | Merck & Co., Inc. | Adenovirus vectors generated from helper viruses and helper-dependent vectors |
| US6730507B1 (en) | 1993-06-24 | 2004-05-04 | Merck & Co., Inc. | Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration |
| US7045347B2 (en) | 1993-06-24 | 2006-05-16 | Advec, Inc. | Helper dependent adenovirus vectors based on integrase family site-specific recombinases |
| US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
| WO1998013508A1 (en) | 1996-09-24 | 1998-04-02 | Dana-Farber Cancer Institute | Method of targeting malignant cells using an e2f responsive promoter |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| US20060275262A1 (en) | 2001-07-26 | 2006-12-07 | Mathis James M | Conditionally replicating viruses and methods for cancer virotherapy |
| KR100523028B1 (ko) | 2003-02-27 | 2005-10-20 | 윤채옥 | 개선된 암세포 특이성과 활성을 가지는 사람 텔로미어역전사효소 프로모터 및 이를 포함하는 재조합 벡터 |
| WO2005086922A2 (en) * | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| HUE031689T2 (en) | 2008-12-22 | 2017-07-28 | Targovax Oy | Oncolytic adenoviral vectors and related procedures and applications |
| US20130243731A1 (en) | 2010-09-24 | 2013-09-19 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies |
| AU2011306846B2 (en) | 2010-09-24 | 2015-05-14 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| ES2534782T3 (es) | 2012-02-02 | 2015-04-28 | Baylor College Of Medicine | Sistema biológico de administración y expresión basado en adenovirus para uso en el tratamiento de la osteoartritis |
| ES2802878T3 (es) | 2013-01-25 | 2021-01-21 | Baylor College Medicine | Un sistema de administración y expresión de terapia génica adenoviral dependiente de linfocitos T colaboradores |
| JP6576326B2 (ja) | 2013-03-14 | 2019-09-18 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍溶解性アデノウイルス組成物 |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| CN106831987B (zh) * | 2015-12-04 | 2020-01-21 | 浙江大学 | 一种抗人her2抗体及其编码基因和应用 |
| CN106831986B (zh) * | 2015-12-04 | 2020-01-21 | 浙江大学 | 一种抗人her2抗体及其编码基因和应用 |
| AU2018254566B2 (en) * | 2017-04-21 | 2025-02-13 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
-
2018
- 2018-04-20 AU AU2018254566A patent/AU2018254566B2/en active Active
- 2018-04-20 KR KR1020247016403A patent/KR20240093758A/ko active Pending
- 2018-04-20 CA CA3060573A patent/CA3060573A1/en active Pending
- 2018-04-20 TW TW107113504A patent/TWI799411B/zh active
- 2018-04-20 NZ NZ758626A patent/NZ758626A/en unknown
- 2018-04-20 US US16/607,066 patent/US11896634B2/en active Active
- 2018-04-20 WO PCT/US2018/028577 patent/WO2018195427A2/en not_active Ceased
- 2018-04-20 JP JP2019556860A patent/JP7260173B2/ja active Active
- 2018-04-20 KR KR1020197033577A patent/KR102830905B1/ko active Active
- 2018-04-20 EP EP18725690.4A patent/EP3612202A2/en active Pending
- 2018-04-20 SG SG11201909749P patent/SG11201909749PA/en unknown
- 2018-04-20 CN CN201880042149.2A patent/CN110785180B/zh active Active
-
2019
- 2019-06-03 US US16/430,347 patent/US10716818B2/en active Active
-
2023
- 2023-03-30 JP JP2023054969A patent/JP7620994B2/ja active Active
-
2025
- 2025-05-09 AU AU2025203355A patent/AU2025203355A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517635A5 (OSRAM) | ||
| JP2013107899A5 (OSRAM) | ||
| Belousova et al. | Genetically targeted adenovirus vector directed to CD40-expressing cells | |
| JP2017537622A5 (OSRAM) | ||
| JP2019531728A5 (OSRAM) | ||
| JP2009544318A5 (OSRAM) | ||
| JP2015096070A5 (OSRAM) | ||
| JP2017513502A5 (OSRAM) | ||
| JP2015509707A5 (OSRAM) | ||
| JP2017163973A5 (OSRAM) | ||
| JP2019531093A5 (OSRAM) | ||
| CN114317461A (zh) | 表达免疫细胞刺激受体激动剂的腺病毒 | |
| RU2015155821A (ru) | Вакцины против малярии | |
| JP2010519931A5 (OSRAM) | ||
| JP2013517783A5 (OSRAM) | ||
| JP2015525230A5 (OSRAM) | ||
| JP2016513471A5 (OSRAM) | ||
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| JP2019519529A5 (OSRAM) | ||
| JP2018505893A5 (OSRAM) | ||
| Lin et al. | Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo | |
| JP2017507943A5 (OSRAM) | ||
| WO2009055491A3 (en) | Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres | |
| JP2015532265A5 (OSRAM) | ||
| JP2015524413A5 (OSRAM) |